Successful pharmaceuticals company in world :: High level business

www.tajpharmaceuticals.com
www.tajapi.com

More than 200,000 Australians benefit from Taj pharmaceuticals limited medicines every day

AstraZeneca is one of the world's largest and most successful pharmaceutical companies.
AstraZeneca Australia is engaged in the research, development, manufacture and supply of medicines that aim to make a real difference for patients in important areas of healthcare.
AstraZeneca excels in providing healthcare solutions designed to fight diseases in seven major therapeutic areas including cardiovascular, neuroscience, gastrointestinal, infection, oncology, anaesthesia (including pain management) and respiratory products.
Generic name: Piracetam
Brand name: Piracetam 800

Description
Piracetam is an agent which is a psychotropic drug. It enhances the functionality of the brain involved in cognitive operations, such as memory, thorough learning in normal and in subnormal conditions. The drug can be used to protect intellectual cortex against hypoxia. The beneficial actions of this medicine are due to the improved microclimate that promotes the metabolism and regulates neuro-transmission.

Uses
Piracetam injection is used in cases of severe brain disorders, like cerebro-cranial injury in acute stage, unconscious states, acute psychic disturbances due to intoxications. Piracetam is used in cerebro-vascular disease, vestibulopathies, cortical myoclonia, protection of the nervous tissue in a brain hypoxia, postoperative deliriums.

Dosage
The drug is administered intramuscularly, as a drop intravenous or as a slow intravenous infusion. The recommended 24-hours dose is 3 - 12 g (depending on the severity of the disease). Oral administration. starting dose - 800 mg , 3 times daily. After the desired effect has been achieved the dose can be reduced to 400 mg , 3 times daily. Administration of the drug in the evening should be avoided because of its exciting action and the possibility of interuppting night sleep of the patient. The duration of the treatment is 2 - 3 months, but in severe special cases the drug can be used for a period of 6 – 12. months.
Safety tips

* You should tell your health care
officer if you have allergy to Piracetam or any other chemical drugs.
* Your doctor
should be well aware of your medical history.
* You should tell your doctor if you ever had heart valve disease or high blood pressure.
* You should tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding.

Common side effects
Immediately call your Doctor if you find any of the following symptoms:

* skin rash, itching, or hives
* swelling in the face, lips, or mouth
* tingling sensations
* fever
* irregular heartbeat
* increases in blood pressure and heart rate
* chest pain
* shortness of breath

- Amlodipine Besylate
- Aciclovir
- Atorvastatin
- Atenolol
- Azithromycin
- Allopurinol
- Bisacodyl
- Cyproheptadine
- Cefuroxime Axetil
- Cefixime
- Cetrizine Hydrochloride
- Ciprofloxacin
- Cephalexin
- Chloroquine
- Diclofenac
- Domperidone
- Enalapril Maleate
- Erythromycin Estolate
- Ethamsylate
- Fexofenadine
- Fluconazole
- Gliclazide
- Glipizide
- Glibenclamide
- Gatifloxacin
- Hyosine Butyl Bromide
- Isosorbide Mononitrate
- Ketoconazole
- Losartan Potassium
- Lovastatin
- Levofloxacin
- Lisinopril (Anhydrous)
- Loratidine
- Levocetrizine
- Levamisole Hydrochloride
- Mecobalamin
- Metformin Hydrochloride
- Metocloperamide
- Norethindrone Acetate
- Nimesulide
- Ofloxacin
- Piroxicam
- Pantoprazole
- Paracetamol
- Prazosin
- Roxithromycin
- Ramipril
- Sildenafil Citrate
- Secnidazole
- Serratiopeptiadase
- Tadalafil
- Tinidazole
Hide
Capsule
- Alfacalcidol
- Ampicillin
- Amoxycillin
- Cephalexin
- Celecoxib
- Doxycycline
- Lansoprazole
- Omeprazole
Injection
- Analgin Injection
- Adenosine Injection
- Ardeparin
- Baralginus Injection
- Ceftriaxone
- Cisplatin Injection
- Cyclophosphamide Injection
- Choriogonadotrophin Alfa
- Docetaxel Injection
- Dalteparin Injection
- Dobutamine Hydrochloride
Injection
- Erythropoietin Injection
- Gemcitabine Injection
- Gatifloxacin
- Ifosfamide Injection
- Lincomycin Injection
- Levetiracetam Injection
- Methotrexate Injection
- Mesna Injection
- Moxifloxacin
- Nimodipine Injection
- Noradrenaline
- Oxaliplatin Injection
- Omeprazole Injection
- Pantoprozole Injection
- Piracetam Injection
- Propofol
- Somatropin Injection
- Somatostatin
- Streptokinase Injection
- Tinzaparin
- Vinblastine Injection
- Zolendronic Acid
Birth Control Device
- Condoms
- Clotrimazole
Hide
Ointments
- Betamethasone
- Clotrimazole Cream
- Diclofenac
- Ketoconazole
- Ciprofloxacin
- Povidone-Iodine
- Norfloxacin
- Ofloxacin
- Polymyxin-B
- Soframycin
- Tobramycin + Dexamethasone
Hide
Syrups
- Ambroxol
- Amoxicillin
- Bromhexine
- Cefpodoxime Proxetil
- Cefixime
- Cefadroxil
- Cephalexin
- Cefuroxime
- Cefaclor
- Clarithromycin
- Cloxacillin
- Cetirizine Hydrochloride
- Paracetamol
- Chlorpheniramine Maleate
- Dextromethorphan
- Erythromycin
- Ephedrine/Guaifenesin Syrup
- Iron Tonic
- Multivitamins
- Phenylephrine
- Pseudoephedrine
- Protein Powder
- Salbutamol
Hide
Pharmaceutical Drugs
Prescription Drugs
- Anti-convulsant Drugs
- Anti-Angina Drugs
- Anti-Fungal Drugs
- Anti-Itch Drugs
- Anti-Viral Drugs
- Anti-Diabetic Drugs
- Anti-Asthmatic Drugs
- Anti-Hypertensive Drugs
- Antibiotics
- Anti-Migraine Drugs
- Anti-Rheumatic Drugs
- Anti-Protozoal Drugs
- Tricyclic Anti-depressants
- Anti-Arrhythmic Drugs
- Anti-nausea Drugs
- Anti- Parkinson Drugs
- Anti-Psychotic Drugs
- Muscle Relaxants
- Digitalis Drugs
- Anti-Gastroesophageal Reflux Drugs
- Anti-Retroviral Drugs
- Anti-Tuberculosis Drugs
- Anti-Ulcer Drugs
- Anti-Hemorrhoid Drugs
- Anti-Spasmodic Drugs
- Anti-malarial Drugs
- Non-steroidal Anti-inflammatory Drugs
- Immuno-Suppressant Drugs
- Anti-Insomnia Drugs
- Anti-helminthic Drugs
- Central Nervous System Stimulants
- Decongestants
- Anti-Coagulant Drugs
- Bone Disorder Drugs
- Infertility Drugs
- Topical Antibiotics
- Diuretics
- Vasodilators:
- Blood-viscosity Reducing Drugs
- Beta Blockers
- Corticosteroids
- Benzodiazepines
- Cephalosporins
- Expectorants
- Sulfonamides
- Calcium Channel Blockers
- Gout Drugs
- Anti-histamines
- Penicillins
- Barbiturates
- Laxatives
- ACE inhibitors
- Anti-anxiety Drugs
- Urinary Anti-infectives
- MAO Inhibitors
- Opioid Analgesics
- Bronchodilators
- Ophthalmic Antibiotics
- Smoking Cessation Drugs
- Protease Inhibitor
- Anti-depressant Drugs
- Alpha1-adrenergic Blockers
- Tetracyclines
Hide
Non-Prescription Drugs
- Anti-Hemorrhoid Drugs
- Anti-acne Drugs
- Antiseptics
- Analgesics
- Aspirin
- Antacids
- Anti-Histamines
- Anti-gas Agents
- Anti-fungal Drugs
- Cough-Suppressants
- Decongestants
- Expectorants
- Non-steroidal Anti-inflammatory Drugs
- Vasodilators
- Smoking Cessation Drugs
- Topical Antibiotics
Hide

Glossary
Pharmaceutical
Abbreviations
Commonly used
abbreviations
Acronyms
Glossary of Terms
British Pharma
Abbreviations

Zeneca Pharmaceuticals: Companies

Investors greeted the news of the merger warmly: the day after the union was announced, Astra's share price increased 13 percent, and Zeneca's rose 7.5 percent. The new company, AstraZeneca PLC, would be the number three pharmaceuticals firm in the industry. The US$37 billion merger was completed on April 6, 1999, 80 days after its announcement, and the new company's stock was listed on the London, Stockholm, and New York stock exchanges. AstraZeneca was headed by Tom McKillop (formerly the CEO of Zeneca) as Chief Executive, and Percy Barnevik (of Astra) as Chairman. In many ways, the two companies seemed a perfect match for one another. They were of comparable size to each other (valued at over US$30 billion each), so they entered the merger on equal footing.

Source:

Zeneca Group PLC is one of the largest and most successful pharmaceutical companies in the world. Actually, the company is divided into three primary business operations, including: Zeneca Pharmaceuticals, which develops medicines for cancer, musculoskeletal, central nervous system, metabolism and endocrinology, infection and respiratory ailments; Zeneca Agrochemicals, which researches and develops crop protection products; and Zeneca Specialties, which develops and manufactures a wide range of products such as resins, biocides, and leather coatings. During 1996, the company developed such innovative products as Casodex, an advanced prostate cancer treatment; Zoladex LA, the first long-acting, slow release prostate cancer treatment; Arimidex, a major advance in breast cancer treatment; Accolate, an innovative oral anti-asthma treatment; Zomig, a quick-acting antimigraine therapy; and Amistar, a new fungicide that can be used on a wide variety of crops. One of the company's most successful subsidiaries is Salick Health Care, Inc., located in the United States. Salick Health Care is gaining a reputation for itself as the leading multisite provider of cancer diagnostic and treatment services. The year 1996 was the best to date for the company, with revenues reaching £5.4 billion, profits passing the £1 billion mark for the first time, and exports exceeding £2 billion, making Zeneca one of the United Kingdom's largest exporters.

Source:

Bob started COMPLETE HEALTHCARE COMMUNICATIONS, INC. (CHC) in 1994 after 11 years on the client side of the pharmaceutical industry at Zeneca Pharmaceuticals (now AstraZeneca). Bob held positions in sales, marketing (ethical, direct-to-consumer, and trade), public and professional relations, managed care contracting and marketing, and finance. Bob ... spent 3 years working for Zeneca in the United Kingdom where he held positions in international product management, business development, and finance. His broad experience helped Bob head Zeneca’s contracting department for developing, negotiating, and managing product contracts with managed care, government, and group buying organizations. He was named the first marketing manager for Zeneca’s managed care department and was instrumental in helping develop Zeneca’s reputation as one of the country’s leading pharmaceutical companies as rated by managed care organizations. As founder, president, and CEO, Bob has an unparalleled passion for CHC and the long-term relationships with large and small pharmaceutical companies CHC has developed.

Source:

Zeneca Ltd. was established as a 100 percent wholly owned subsidiary of ICI on January 1, 1993. By June of the same year... Zeneca existed as a totally separate company from ICI. Zeneca's market capitalization was actually more than that of ICI and placed the newly established company in the top 25 firms listed with the highest capitalization in the United Kingdom. A new headquarters was set up for Zeneca at 15 Stanhope Gate, having been custom-designed to meet the specific needs of the new organization. By the end of fiscal 1993, the first full year of Zeneca's operation, sales had increased approximately 12 percent to an impressive total amount of £4.44 billion, and the company's profit margin increased by an astounding 42 percent to £647 million. Zeneca's pharmaceutical operation immediately catapulted it into the ranks of the top 20 pharmaceutical companies worldwide.

Source:

Shortly after the transaction, the clinics' founder, Bernard Salick, MD, announced his resignation, saying that Zeneca had offered him a watered-down post with few of his usual responsibilities. He ... announced plans to launch a competing company. The move came as a surprise since Salick had originally planned to stay on board and serve as a buffer between the drugmaker and the hospitals.

Source:

The National Women's Health Network urged the FDA to demand that Zeneca pull the ads because they presented a misleading visual image of the group that would benefit from the drug. The FDA reviewed Zeneca's ad and promotional materials about Nolvadex, and, in January, sent Zeneca a letter detailing the false or misleading claims made in the company's materials and asking that the use of the materials stop immediately.3 With respect to the MAMM ad, the FDA identified the following problems: the ad failed to provide adequate information about the approved use of the drug; the ad failed to include any information about risks from the drug, and the ad failed to present even a brief summary of the side effects, contraindications and effectiveness of the drug. Zeneca says it has stopped using the materials and ads that the FDA criticized in January.